KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 90 filers reported holding KALVISTA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $23,449,127 | +17.3% | 1,990,588 | +18.1% | 0.00% | – |
Q1 2024 | $19,985,440 | -8.4% | 1,685,113 | -5.4% | 0.00% | – |
Q4 2023 | $21,822,382 | +30.8% | 1,781,419 | +2.8% | 0.00% | – |
Q3 2023 | $16,683,869 | +17.3% | 1,732,489 | +9.6% | 0.00% | – |
Q2 2023 | $14,226,129 | +14.4% | 1,580,681 | -0.1% | 0.00% | – |
Q1 2023 | $12,438,654 | +59.6% | 1,582,526 | +37.3% | 0.00% | – |
Q4 2022 | $7,792,070 | -53.3% | 1,152,673 | +0.2% | 0.00% | – |
Q3 2022 | $16,684,000 | +46.5% | 1,149,861 | -0.6% | 0.00% | – |
Q2 2022 | $11,386,000 | -33.8% | 1,157,158 | -0.8% | 0.00% | – |
Q1 2022 | $17,196,000 | +14.2% | 1,166,652 | +2.5% | 0.00% | – |
Q4 2021 | $15,062,000 | -27.3% | 1,138,484 | -4.1% | 0.00% | -100.0% |
Q3 2021 | $20,709,000 | -10.4% | 1,186,747 | +23.1% | 0.00% | 0.0% |
Q2 2021 | $23,108,000 | -3.2% | 964,419 | +3.8% | 0.00% | 0.0% |
Q1 2021 | $23,878,000 | +121.6% | 929,481 | +63.8% | 0.00% | – |
Q4 2020 | $10,777,000 | +53.2% | 567,548 | +1.6% | 0.00% | – |
Q3 2020 | $7,036,000 | +4.0% | 558,853 | -0.1% | 0.00% | – |
Q2 2020 | $6,768,000 | +57.9% | 559,332 | -0.2% | 0.00% | – |
Q1 2020 | $4,286,000 | -56.2% | 560,193 | +1.8% | 0.00% | – |
Q4 2019 | $9,795,000 | +55.2% | 550,019 | +1.1% | 0.00% | – |
Q3 2019 | $6,312,000 | -46.0% | 544,048 | +3.1% | 0.00% | – |
Q2 2019 | $11,692,000 | +14.3% | 527,829 | +47.7% | 0.00% | – |
Q1 2019 | $10,228,000 | +51.9% | 357,390 | +4.9% | 0.00% | – |
Q4 2018 | $6,732,000 | +2.7% | 340,843 | +14.9% | 0.00% | – |
Q3 2018 | $6,558,000 | +587.4% | 296,581 | +152.4% | 0.00% | – |
Q2 2018 | $954,000 | -14.1% | 117,489 | +0.3% | 0.00% | – |
Q1 2018 | $1,110,000 | -3.8% | 117,095 | -1.1% | 0.00% | – |
Q4 2017 | $1,154,000 | -13.2% | 118,338 | -40.7% | 0.00% | – |
Q3 2017 | $1,330,000 | +2.1% | 199,618 | +10.4% | 0.00% | – |
Q2 2017 | $1,303,000 | -7.7% | 180,872 | +0.1% | 0.00% | – |
Q1 2017 | $1,412,000 | +407.9% | 180,772 | +360.0% | 0.00% | – |
Q4 2016 | $278,000 | – | 39,296 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SV Health Investors, LLC | 2,579,490 | $20,146,000 | 22.25% |
Novo Holdings A/S | 2,901,927 | $22,664,000 | 2.41% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 322,436 | $2,518,000 | 0.96% |
Vivo Capital, LLC | 300,325 | $2,346,000 | 0.69% |
VHCP Management II, LLC | 221,651 | $1,635,000 | 0.67% |
RA Capital Management | 591,070 | $4,616,000 | 0.57% |
INTERWEST VENTURE MANAGEMENT CO | 329,942 | $2,577,000 | 0.55% |
Eventide Asset Management | 98,100 | $766,000 | 0.05% |
BOOTHBAY FUND MANAGEMENT, LLC | 21,665 | $169,000 | 0.03% |
A.R.T. Advisors, LLC | 11,116 | $86,000 | 0.00% |